LOWELL, Massachusetts, Jan. 8, 2014 /PRNewswire/ -- InfoBionic™, an emerging digital health company focused on creating superior patient monitoring solutions for chronic disease management, today announced receipt of CE Mark for the MoMe™ System for cardiac arrhythmia monitoring. The MoMe System is the first universal remote patient monitoring platform with seamless transition between Holter, Event, and Mobile Cardiac Telemetry (MCT) modes. The innovative platform, which leverages Cloud computing and proprietary analytics, is poised to revolutionize the $3B worldwide cardiac monitoring market by delivering on-demand access to patient data for diagnosis.
The MoMe System draws on the recent convergence of medical devices, database analytics, new sensors, and wireless protocols to provide a universal patient monitoring platform complete with real-time, high-quality patient data for improved arrhythmia detection.
"Existing cardiac patient monitoring systems have significant limitations, including poor data quality and limited data availability," stated Liviu Klein, M.D., UCSF Heart and Vascular Center. "The MoMe System provides high-quality data and real-time rhythm history as well as activity, respiration and symptom tracking that allows me to make a fast, accurate, timely and efficient medical diagnosis."
Nancy Briefs, Chief Executive Officer, commented, "We are pleased to receive CE Mark for the MoMe System. We believe the system will transform the arrhythmia monitoring market by offering superior arrhythmia detection and favorable physician practice economics. We look forward to commercializing our first product for cardiac arrhythmia monitoring in early 2014."
InfoBionic™ Inc., an emerging digital health company is dedicated to transforming healthcare delivery by providing anywhere, anytime access to cardiac event monitoring with improved event detection and clinical efficacy through a lower cost business model. The MoMe™ System offers superior remote patient monitoring for chronic diseases with an initial market focus on cardiac arrhythmias.
For more information please visit www.infobionic.com.
SOURCE InfoBionic Inc.